Shire Buying ViroPharma To Create Leading Rare Disease Group
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire is snapping up ViroPharma at a hefty premium to secure possession of C1 esterase inhibitor Cinryze and position the group as a formidable force in treatments for rare diseases.